The bottleneck is inside and being paid away

Illumina, Inc. (ILMN) — this company's answers

The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that the main thing standing between the company and meaningfully more business is the company's own capability (capacity, people, facilities, throughput, ability to deliver), and that they are already spending real money and effort to remove that internal limit, with business waiting on the other side visible. We need to check for the three conditions: (1) live demand pressing in, (2) the limit is company's own capability, (3) removal already underway. Let's analyze the transcript. Management talks about strong revenue, growth, but they also talk about guidance, forecasting, and factors like seasonality. They mention growth in consumables, microarray, etc. They discuss investments and R&D projects. But do they say they can't meet demand because of capacity? No. They say "we have got some tremendous momentum" but they don't mention any capacity constraints. They talk about timing of headcount additions and investments. They mention that they're planning incremental R&D and commercial projects to capitalize on momentum. But that's more about future investment, not about current capacity constraints. They talk about NovaSeq shipments, and they say "we continue to be very pleased with how the NovaSeq rollout is going" and that they expect it to be a multiyear adoption cycle. They don't say they can't ship enough because of capacity. They mention iSeq shipping beta units and scaling shipments midyear. That's about product launch, not capacity. They also talk about microarray service revenue doubling, but they don't say they can't serve all demand. The question is about whether management conveys that the main thing standing between more business is their own capability. I don't see that. They talk about demand being strong, and they are investing to drive future growth, but not that they are constrained. They also mention "we are planning some incremental R&D and commercial projects to capitalize on the momentum" but that's about future investment, not about current capacity constraints. Also, the question asks about "the business waiting on the other side already visible today" - meaning they have customers waiting. I don't see that. They do mention that they expect gross margins to decline due to mix and higher costs associated with pharma collaborations, but that's not about capacity. Thus, the answer is NO.

← Back to the full ILMN analysis